



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

CRIZotinib (Xalkori®)



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): First-line therapy of advanced stage ALK positive or ROS1 positive lung adenocarcinoma.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
CRIZotinib	250 mg PO bid	To be given without regard to food. If a dose is missed, take it as soon as remembered unless it is less than 6 hrs prior to the next scheduled dose. Don't take 2 doses at the same time to make up for a missed dose. If vomiting occurred after a dose, administer the next dose at the scheduled time.
To be given continuously until disease progression or intolerable toxicity.		

- Special instructions:**
- Avoid grapefruit and grapefruit juice.
 - Avoid Acid-suppressive drugs such as proton-pump inhibitors, H2 antagonists, and antacids.
 - Avoid drugs that prolong the QT interval.
 - Avoid concomitant use with strong CYP3A4 inducers (Anticonvulsants) and inhibitors.
 - Avoid concomitant use with Antifungals (voriconazole), Clarithromycin, and Opiate agonists (fentanyl).

Treatment Description:

Cycle	Date	CRIZotinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No